Divisions of Research Administration and Interventional Cardiology, Hartford Hospital, Hartford, Connecticut, USA.
Am J Gastroenterol. 2020 Oct;115(10):1617-1623. doi: 10.14309/ajg.0000000000000832.
To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine.
Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020.
Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated with famotidine, patients treated with famotidine were younger (63.5 ± 15.0 vs 67.5 ± 15.8 years, P = 0.021), but did not differ with respect to baseline demographics or preexisting comorbidities. Use of famotidine was associated with a decreased risk of in-hospital mortality (odds ratio 0.37, 95% confidence interval 0.16-0.86, P = 0.021) and combined death or intubation (odds ratio 0.47, 95% confidence interval 0.23-0.96, P = 0.040). Propensity score matching to adjust for age difference between groups did not alter the effect on either outcome. In addition, patients receiving famotidine displayed lower levels of serum markers for severe disease including lower median peak C-reactive protein levels (9.4 vs 12.7 mg/dL, P = 0.002), lower median procalcitonin levels (0.16 vs 0.30 ng/mL, P = 0.004), and a nonsignificant trend to lower median mean ferritin levels (797.5 vs 964.0 ng/mL, P = 0.076). Logistic regression analysis demonstrated that famotidine was an independent predictor of both lower mortality and combined death/intubation, whereas older age, body mass index >30 kg/m, chronic kidney disease, National Early Warning Score, and higher neutrophil-lymphocyte ratio were all predictors of both adverse outcomes.
Famotidine use in hospitalized patients with COVID-19 is associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower levels of serum markers for severe disease in hospitalized patients with COVID-19.(Equation is included in full-text article.).
比较接受法莫替丁治疗和未接受法莫替丁治疗的因冠状病毒（COVID-19）住院患者的结局。
这是一项 2020 年 2 月 24 日至 5 月 13 日连续收治的 COVID-19 阳性患者的回顾性、倾向评分匹配的观察性研究。
在分析的 878 例患者中，有 83 例（9.5%）接受了法莫替丁治疗。与未接受法莫替丁治疗的患者相比，接受法莫替丁治疗的患者更年轻（63.5±15.0 岁比 67.5±15.8 岁，P=0.021），但基线人口统计学特征或预先存在的合并症无差异。使用法莫替丁与住院死亡率降低相关（比值比 0.37，95%置信区间 0.16-0.86，P=0.021），与死亡或插管的复合终点降低相关（比值比 0.47，95%置信区间 0.23-0.96，P=0.040）。倾向评分匹配以调整两组间的年龄差异并未改变这两种结局的影响。此外，接受法莫替丁治疗的患者血清严重疾病标志物水平较低，包括中位峰值 C 反应蛋白水平（9.4 比 12.7mg/dL，P=0.002）、中位降钙素原水平（0.16 比 0.30ng/mL，P=0.004）和中位平均铁蛋白水平呈下降趋势（797.5 比 964.0ng/mL，P=0.076）。Logistic 回归分析表明，法莫替丁是死亡率和死亡/插管复合终点降低的独立预测因子，而年龄较大、体重指数＞30kg/m、慢性肾脏病、国家早期预警评分和较高的中性粒细胞/淋巴细胞比值均是这两种不良结局的预测因子。
COVID-19 住院患者使用法莫替丁与死亡率降低、死亡率和插管复合终点降低以及 COVID-19 住院患者严重疾病血清标志物水平降低相关。
